Polytech is a leading player in Europe in the development and production of silicone implants and is the sole German manufacturer of such products. The company specialises in breast implants used in reconstructive surgery after illness and in aesthetic plastic surgery.

The company has grown strongly in recent years. This expansion is based on production (under clean-room conditions) in Germany, which conforms to the highest quality standards, and the company’s innovative capacity. Polytech has developed surface textures for its products that lead to a clear reduction in the rate of complications.

In view of the very positive response to implants “Made in Germany”, Polytech has considerably expanded its sales activities. At the moment, the company generates around 40 per cent of its revenues in Germany and around 30 per cent in other European countries. However, its implants are increasingly being distributed worldwide, currently in over 70 countries. Polytech serves a growth market, driven by a number of factors including rising prosperity and demographic change in industrialised countries.

Since the beginning of the investment, Polytech has continued on its path with sustained growth dynamics; the company is also planning to achieve higher sales in the 2019 financial year than in the previous year. This is due to market share gains in the economic area of Europe, the Middle East and Africa, especially in Germany and Italy. They are based on Polytech's leading and innovative product portfolio, which was further broadened by the merger with G&G Biotechnology in 2018. G&G had developed the world's first breast implant with reduced weight (lightweight implants).

The merger with G&G Biotechnology should enable Polytech to further strengthen its leading market position in Europe and to expand internationally. In order to be able to meet the increasing demand in the future, the company is working on further expanding its capacities. In 2020, sales and earnings are expected to be higher than in the previous year, based on the planned stronger market penetration of the new lightweight implants and a more intensive cultivation of existing markets.